MedTrace Logo

Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)

NCT02193880 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-04-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of post-transplant cyclophosphamide and a post-transplant infusion of donor cells, that have been specially processed to remove alpha beta t-cells, in patients undergoing a haploidentical allogeneic stem cell transplant to help reduce the risk of relapse without increasing the risk of graft-versus-host disease.

Conditions

  • Hematologic Neoplasms
  • Graft-Versus-Host Disease

Interventions

DEVICE

Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.

Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.

Sponsors & Collaborators

  • Ayman Saad

    lead OTHER

Principal Investigators

  • Ayman Saad, MD · University of Alabama at Birmingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-09
Primary Completion
2018-03-13
Completion
2018-03-13
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02193880 on ClinicalTrials.gov